ArticleFrontiers in pediatrics2026
Pediatric pleural empyema - decision making beyond imaging - a retrospective cohort study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: In children and infants, thoracic empyema most often develops as a complication of parapneumonic pleural effusions progressing to purulent collections. With an estimated incidence of approximately 0.6% among pediatric pneumonia cases, empyema remains associated with significant morbidity. This study aimed to characterize pediatric parapneumonic empyema by analyzing clinical, biochemical, and radiological parameters and their relationship with treatment decisions and outcomes. Materials and methods: We conducted a retrospective, single-center study including children diagnosed with parapneumonic pleural empyema and treated in the Pulmonology Department of the "Grigore Alexandrescu" Emergency Hospital for Children between January 2021 and December 2024. Only patients managed surgically-either by chest-tube drainage or video-assisted thoracic surgery (VATS)-were included. Fibrinolytic therapy was not used due to limited institutional experience, with VATS preferred in complicated cases. Patients were stratified according to initial intervention. Clinical, laboratory, and imaging data were extracted from medical records. Results: A total of 33 patients were included, with a median age of 4 [3-8] years. The median time to initial intervention was 2 [1-5] days. Fourteen patients (42.4%) underwent primary VATS after a median of 4.5 [2-6.3] days, while 19 received initial chest-tube drainage after 1 [0-3] days, with a mean drainage duration of 21.2 ± 11.5 days. Median hospital stay for the cohort was 27 [21-38.5] days. Loculations and septations were significant predictors of hospitalization length. Drainage duration was significantly shorter in the primary VATS group compared with the chest-tube group (9.5 [7.8-12.5] vs. 19 [11-30] days; Conclusions: Chest-tube drainage was the most frequent initial treatment, with escalation decisions driven primarily by clinical presentation rather than imaging or biochemical markers. Thoracic ultrasound was valuable for assessing effusion complexity but had limited prognostic utility. The lack of fibrinolytic therapy resulted in a high rate of VATS, highlighting the need for standardized, symptom-driven management algorithms integrating clinical, laboratory, and imaging data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.